Multivalent vaccines for rabies virus and filoviruses

Patent metadata

Field	Value
Publication number	US-10849975-B2
Application number	US-201213983545-A
Country	US
Kind code	B2
Filing date	Feb 2, 2012
Priority date	Feb 3, 2011
Publication date	Dec 1, 2020
Grant date	Dec 1, 2020

Abstract

The present invention provides methods and compositions for inducing an immune response that confers dual protection against infections by either or both of a rabies virus and a filovirus, and/or which can be used therapeutically for an existing infection with rabies virus and/or a filovirus to treat at least one symptom thereof and/or to neutralize or clear the infecting agents. In particular, the present invention provides a recombinant rabies virus vector comprising a nucleotide sequence encoding at least one filovirus glycoprotein or an immunogenic fragment thereof, as well as pharmaceutical compositions comprising the vaccine vectors.

First claim

What is claimed is:

1. A composition comprising a therapeutically effective amount of a recombinant multivalent rabies virus vector comprising a nucleotide sequence encoding at least one filovirus glycoprotein which is incorporated into the rabies virus virion, wherein the rabies virus genome is attenuated and, wherein the therapeutically effective amount of said recombinant multivalent rabies virus vector is an amount sufficient to induce an immune response that is protective against a rabies virus infection and a filovirus infection and that includes neutralizing antibodies to the rabies virus and the filovirus.

2. The composition of claim 1 , wherein the at least one filovirus glycoprotein is Ebolavirus glycoprotein.

3. The composition of claim 1 , wherein the at least one filovirus is Zaire Ebolavirus (ZEBOV), Sudan Ebolavirus (SEBOV), Cote d'Ivoire Ebolavirus (CEBOV), Reston Ebolavirus (REBOV), Bundibugyo Ebolavirus (BEBOV), or Marburgvirus.

4. The composition of claim 1 , wherein the glycoprotein comprises the amino acid sequence of SEQ ID NO: 1 (from ZEBOV), SEQ ID NO: 2 (from SEBOV), SEQ ID NO: 3 (from CEBOV), SEQ ID NO: 4 (from REBOV), SEQ ID NO: 5 (from BEBOV), or SEQ ID NO: 6 (from Marburgvirus).

5. The composition of claim 1 , wherein the rabies virus vector is derived from the live attenuated SAD B19 RABV vaccine.

6. The composition according to claim 1 , wherein the rabies virus genome further expresses one or more additional filovirus proteins.

7. The composition according to claim 6 , wherein the one or more filovirus proteins are selected from the group consisting of a nucleoprotein (NP), VP40, VP35, VP30, VP24, and an RNA-dependent RNA polymerase (L) from an Ebolavirus or Marburgvirus.

8. A multivalent immunogenic composition, comprising a therapeutically effective amount of a recombinant rabies virus vector that expresses at least one filovirus glycoprotein which is incorporated into the rabies virus virion, wherein the rabies virus genome is attenuated and, wherein the therapeutically effective amount of said multivalent immunogenic composition is an amount sufficient to induce an immune response that is protective against a rabies virus infection and a filovirus infection and that includes neutralizing antibodies to the rabies virus and the filovirus.

9. The multivalent immunogenic composition according to claim 8 , wherein the at least one filovirus glycoprotein is Ebola glycoprotein.

10. The multivalent immunogenic composition according to claim 8 , wherein the at least one filovirus is ZEBOV, SEBOV, CEBOV, REBOV, BEBOV or Marburgvirus.

11. The multivalent immunogenic composition according to claim 8 , wherein the Ebola glycoprotein comprises the amino acid sequence of SEQ ID NO: 1 (from ZEBOV), SEQ ID NO: 2 (from SEBOV), SEQ ID NO: 3 (from CEBOV), SEQ ID NO: 4 (from REBOV), SEQ ID NO: 5 (from BEBOV), or SEQ ID NO: 6 (from Marburgvirus).

12. The multivalent immunogenic composition according to claim 8 , wherein the rabies virus genome is derived from the live attenuated SAD B19 RABV vaccine.

13. A pharmaceutical composition comprising the composition of claim 1 and a pharmaceutically acceptable carrier.

14. The pharmaceutical composition according to claim 13 , further comprising at least one additional therapeutic agent.

15. The multivalent immunogenic composition according to claim 8 , wherein the rabies virus genome further expresses one or more additional filovirus proteins.

16. The multivalent immunogenic composition according to claim 15 , wherein the one or more filovirus proteins are selected from the group consisting of a nucleoprotein (NP), VP40, VP35, VP30, VP24, and an RNA-dependent RNA polymerase (L) from an Ebolavirus or Marburgvirus.

17. The multivalent immunogenic composition according to claim 15 , wherein the one or more additional filovirus proteins is a structural or nonstructural protein from a Marburgvirus.

18. A pharmaceutical composition comprising one or more multivalent immunogenic compositions according to claim 8 and a pharmaceutically acceptable carrier.

19. The pharmaceutical composition according to claim 18 , further comprising at least one additional therapeutic agent.

20. The pharmaceutical composition according to claim 19 , wherein the therapeutic agent is an anti-viral drug, and anti-viral antibody, an immunostimulatory agent, or an adjuvant.

21. The composition according to claim 6 , wherein the one or more additional filovirus proteins is a structural or nonstructural protein from a Marburgvirus.

22. A method of treating a subject infected with a filovirus and/or a rabies virus, comprising administering to the subject a therapeutically effective amount of the composition of claim 1 , wherein the composition is effective at treating the subject.

23. A method of treating a subject infected with a filovirus and/or a rabies virus, comprising administering to the subject a therapeutically effective amount of the composition of claim 8 , wherein the composition is effective at treating the subject.

24. A method of inducing an immune response protective against a filovirus and a rabies virus in a subject, the method comprising administering to the subject the composition of claim 1 .

25. A method of inducing neutralizing antibodies against a filovirus and a rabies virus in a subject, comprising administering to the subject the composition of claim 1 , wherein the composition is effective at inducing neutralizing antibodies against the filovirus and the rabies virus.

26. A method of inducing neutralizing antibodies against a Filovirus and a rabies virus in a subject, comprising administering to the subject the composition of claim 9 , wherein the composition is effective at inducing neutralizing antibodies against the Filovirus and the rabies virus.

Assignees

• Blaney Joseph E
• Paragas Jason
• Jahrling Peter
• Johnson Reed
• Schnell Matthias
• Univ Jefferson
• The Us Secretary Department Of Health And Human Services Services

Inventors

• Blaney Joseph E
• Paragas Jason
• Jahrling Peter
• Johnson Reed
• Schnell Matthias

Classifications

• A61K39/12 Primary

  Viral antigens · CPC title

• C12N2760/20043

  viral genome or elements thereof as genetic vector · CPC title

• C12N2760/20143

  viral genome or elements thereof as genetic vector · CPC title

• C12N2760/20134

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C12N2760/14234

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title